Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
Ist die Zulassung das einzige Ziel? Eine Übersicht über aktuelle
Entwicklungen in Pharma DiagnostikEntwicklungen in Pharma, Diagnostik und Medizintechnik
Dr. Gabriele Dallmann
VBU-Mitgliederversammlungg g
4. Dezember 2012
Dr Gabriele Schäffner-Dallmann Focus: BiopharmaceuticalsDr. Gabriele Schäffner-Dallmann. Focus: Biopharmaceuticals
Spezialist für Entwicklung und Zulassung von Biopharmazeutika inkl. ATMPs und Biosimilars
Ex-Regulator PEI: Verantwortlichkeit für Zulassung und
Chargenprüfung aller Antikörper-haltigen A i itt lArzneimittel
EMA: Mitglied in Zulassungs-Gremien und E perten Gr ppenExperten-Gruppen
Entwicklung Regularien und Verfahren B t Beratung Training (EUCRAF)
2
Medicinal Products Medical DevicesDrugs
(Chemical entities)
Biopharmaceuticals(Chemical entities)
AIMD MD IVD
VaccinesCells
Tissuesrec.
ProteinsBlood
Products
Combination Product ? 3
In jedem Fall:In jedem Fall:Einordnung des Produktes gemäß Definition derEinordnung des Produktes gemäß Definition der
Richtlinien bzw Verordnungen Arzneimittel? Medizinprodukt?Medizinprodukt?
Verfahren Zulassung oder Zertifizierung oder Überwachung?
BehördeBehörde Nationale Zulassungsbehörde oder EMA? Notified Body?
Üb h b hö d ? Überwachungsbehörde?4
No “Combination Product” Regulatory Status in Europe medicinal product or medical device definitions
Regulatory status defined by primary mode of action (PMOA):(PMOA):
- Metabolic, pharmacological, immunological Medicinal Product MPD
- Other and in particular mechanical/physical p p yMedical Device MDD/AIMDD/IVD
5
The current Pharma dilemma Assuming a TOP20 Company with 8 new targets, all for
autoimmune diseases such as RA, psoriasis, Crohn‘s disease E h t t i t l l i th l diff ti t Each target unique, central role in pathology, differentiates
patients from healthy subjects, promising based on postulated MoA (Mode of Action)MoA (Mode of Action)
Clinical trial designs take the currently approved products as basisbasis
The dilemma: Physicians do not support them: „we do not see these patients anymorePhysicians do not support them: „we do not see these patients anymore
in our practice“ Clinical trials in other regions suffer from high placebo effects and low
f l i t i it tsuccessful screening rates in recruitment Pricing: HTA agencies are national and require additional benefit
Consequence: the definition “the market” has changed! Consequence: the definition the market has changed! 6
Biological/biotech products BiologicalsNaturally sourced products
Recombinant proteinsrDNA technologyNaturally sourced products
Hormones
rDNA technologyMonoclonal antibodies
Blood products (IVIG, albumin, clotting factors)
ErythropoeitinGrowth hormoneFilgrastimRecombinant hormones
ATMPsGene Therapy Recombinant hormones
Recombinant enzymesGene TherapySomatic Cell Therapy
Recombinant vaccinesFusion proteins
Tissue Engineered Products
7
EU / EEAEU / EEA
Austria (AU) Belgium (BE) Bulgaria (BG) Cyprus (CY) Czech Republic (CZ)
Denmark (DK) Estonia (EE) Finland (FI) France (FR) Germany (DE) Greece (EL)National agencies
Hungary (HU) Ireland (IE) Italy (IT) Latvia (LV) Lithuania (LT)
Luxembourg (LU) Malta (MT) Netherlands (NL) Poland (PL) Portugal (PT) Romania (RO)
Slovakia (SK) Slovenia (SI) Spain (ES) Sweden (SE) United Kingdom (UK)
+EEA (Iceland, Norway, Liechtenstein)
EMA8
EMA
PhPharma
SCIENTIFIC ADVICE Regulatory procedures
CLINICAL TRIAL AUTHORISATION
MARKETING AUTHORISATION
Regulatory procedures
Agencies involvedMARKETING AUTHORISATION
9
AGENCIES INVOLVED
• 31 national agencies and EMAg
SCIENTIFIC ADVICE
N ti ll d t ll (EMA)• Nationally and centrally (EMA)
CLINICAL TRIAL AUTHORISATION
• Nationally but register of clinical trials at EMA
MARKETING AUTHORISATIONMARKETING AUTHORISATION
• Centralised and rarely national (DCP and MRP) procedure
• Experts of national agencies perform the scientific assessment
• EMA as the central administration for the centralised procedure
10
p
Clinical Trials in EU
Ph IPhase I Phase I/IIa Phase IIb Phase III
• AutoimmunePhase I• 1 Phase I
Unit• HV
• 1 Univers. hospital
• Pat. withAuto-immune
• 3 Univers. Hospitals, Tumour patients
• Dosis-Finding• PoC
• Autoimmune disease
prov
al
disease
App
UKDE 12 countries in EU,UK
SE NL, PL, Ukraine
12 countries in EU,Except UK,SwitzerlandUSA
EMAUkraine
11
CTA: relevant guidanceCTA: relevant guidancehttp://ec.europa.eu/health/documents/eudralex/vol-10/
EU Commission
12
MARKETING AUTHORISATION IN EU
1. Centralised Procedure (CP)2. Decentralised Procedure (DCP)3 Mutual Recognition Procedure (MRP)3. Mutual Recognition Procedure (MRP)
13
Is there a choice for biopharmaceuticals?BiologicalsNaturally sourced products
Recombinant proteinsrDNA technologyNaturally sourced products
Hormones
rDNA technologyMonoclonal antibodies
Blood products (IVIG, albumin, clotting factors)
ErythropoeitinGrowth hormoneFilgrastimRecombinant hormones
ATMPsGene Therapy Recombinant hormones
Recombinant enzymesGene TherapySomatic Cell Therapy
Recombinant vaccinesFusion proteins
Tissue Engineered Products
14
Is there a choice for biopharmaceuticals?Is there a choice for biopharmaceuticals?
• Not really• Mainly centralised procedure!• Mainly centralised procedure!• MRP for existing marketing authorisations – all
those for which the centralised procedure is not applicablenot applicable
• DCP only for those which are not eligible for th CPthe CP
15
Agency of the European Union based in Canary Wharf,The EMA
g y p y ,London
Responsible for the administrative and proceduralaspects of EU regulations and directives related to theaspects of EU regulations and directives related to theevaluation and safety monitoring of medicines in the EU
Executive Director and secretariat of ca 550 full-timestaff
Reports to the Pharmaceuticals Unit of the DG Healthand Consumers in the EU Commission (DG SANCO)and Consumers in the EU Commission (DG SANCO)
Independent Management Board responsible forbudgetary and planning matters, monitoring of theAgency’s performance and appointment of theExecutive Director
With the exception of the pediatric activities no scientific
Link to EMA website:
With the exception of the pediatric activities, no scientificassessment and responsibility
16
Link to EMA website:http://www.ema.europa.eu/ema/index.jsp?curl=/pages/home/Home_Page.jsp
17
EMA responsibility: the mandatory scope of the centralised procedure
(Regulation 726/2004)
18
Centralised Procedure mandatory for
– Biotech products – ATMPsATMPs– New active substances for treatment of:
• AIDSAIDS• Cancer• Neurodegenerative disorders
Di b t• Diabetes• Auto-immune diseases/immune dysfunction• Viral diseases
– Orphan drugs
19
Centralised Procedure optional forCentralised Procedure optional for
– New active substances (outside mandatoryNew active substances (outside mandatory scope indications)P d t ff i i ifi t th ti– Products offering significant therapeutic, scientific or technical innovation
– Products in the interest of patients at Community levelCommunity level
– Generics of products authorised through the Centralised procedure
20
Centralised Procedure – Key Points
• 1 Marketing Authorisation valid throughout the EU / EEA• 1 Trademark• 1 Legal status• Application submitted to one agency only: EMApp g y y• Review process includes all Member States• It is not possible to withdraw the application from selectedIt is not possible to withdraw the application from selected
Member States during the procedure• Results in a pan-European Decision (positive or negative)Results in a pan European Decision (positive or negative)• Expensive (254,100 Euro basic fee = 1 strength associated with
1 pharmaceutical form)1 pharmaceutical form)• Complex logistics and time-lines (submission to approval
14-15 months plus preparation period of 9 months)21
14 15 months plus preparation period of 9 months)
N di i l d t li ti t thNew medicinal product applications at theEMA via the CP
92
Biologicals SM
79
49
2315
10
2009 2010 201120% failed 30% / 10% failed26% / 23% failed20% failed 30% / 10% failed26% / 23% failed
2011: 90 reviewsBiologicals: 10 (11%), 7 positive (70%)SM: 48 (53%) 41 positive (85%)
22
SM: 48 (53%), 41 positive (85%) Generics: 31 (34%), 30 positive (97%)SM + Generics: 79 (88%), 71 positive (90%)
Success RateSuccess Rate
Biopharmaceuticals: Success rate 66-80%Biopharmaceuticals: Success rate 66-80%
Small Molecules: Success rate 80-88%
Main reason for failure for all: clinical dataMain reason for failure for all: clinical data insufficient adherence to regulatory principles in
the clinical development insufficient or irrelevant clinical effect or insufficient or irrelevant clinical effect or
unfavourable safety
23
Authorized and rejected biosimilarsj1 Omnitrope (somatropin) Sandoz Authorised
2 Valtropin (somatropin) Biopartners Authorised
3 Alpheon (IFN alfa-2a) Biopartners Negative
4 Biferonex (IFN beta-1a) Biopartners Negative
5 Binocrit (Epo alfa) Sandoz( )Authorised6 Epoetin alfa Hexal (epo alfa) Hexal
7 Abseamed (epo alfa) Medice
8 Silapo (epo zeta) Stada8 Silapo (epo zeta) StadaAuthorised9 Retacrit (epo zeta) Hospira
10 Epostim (epoetin alfa) ood cell production Reliance GeneMedix Plc Withdrawn
11 I li M l Sh t (h i li ) M l Lif S i‘ Withd (2 )11 Insulin Marvel Short (human insulin) Marvel Lifes Sci‘ Withdrawn (2x)
12 Insulin Marvel Intermediate (human insulin) Marvel Life Sci‘ Withdrawn (2x)
13 Insulin Marvel Long (human insulin) Marvel Life Sci‘ Withdrawn (2x)
14 Filgrastim Ratiopharm (filgrastim) Ratiopharm
Authorised15 Ratiograstim (filgrastim) Ratiopharm
16 Biograstim (filgrastim) CT Arzneimittel GmbH
17 Tevagrastim (filgrastim) Teva
18 Filgrastim Hexal (filgrastim) HexalAuthorised19 Zarzio (filgrastim) Sandoz19 Zarzio (filgrastim) Sandoz
20 Nivestim (filgrastim) Hospira Authorised24
Some players in the field of biosimilar tib diantibodies
Amgen-Watson-PRAAmgen Watson PRA Boehringer Ingelheim
Celltrion Hospira first infliximab under review in EU Celltrion-Hospira first infliximab under review in EU Coherus -Daiichi Sankyo
Merck Hanwha Parexel Merck-Hanwha-Parexel Merck Serono – Dr. Reddys
M l Bi Mylan-Biocon Pfizer
S Bi Q i il Samsung-Biogen-Quintiles Sandoz TEVA
25
26
27
SCIENTIFIC ADVICE IN EUSCIENTIFIC ADVICE IN EU
Regulatory input by agencies regarding Development plan
• e.g. choice of study population, endpoints, statistical plan Submission strategy Risk management
Two routes in Europe National Scientific Advice CHMP Scientific Advice at EMA
Considerations on the scope of the scientific advice: Preparation of the FTIM study,
f / ?
National agencyof the country of
i.e. mainly pre-clinical programme and manufacture/control? Discussion of critical issues related
to the manufacture characterisation
ythe first CTA
Both, national agency of theto the manufacture, characterisation
and testing scheme? Discussion of the whole
agency of thecountry of the firstCTA or EMA
28
clinical development plan? EMA
Medizinprodukte National geregelt - heterogene Behördenlandschaft Richtlinien:
Richtlinie 90/385/EWG über aktive implantierbare Medizinprodukte (AIMD)
Richtlinie 93/42/EWG über Medizinprodukte (MDD) Richtlinie 98/79/EG über In-vitro-Diagnostika (IVDD)
Eigenverantwortlichkeit der Hersteller Anmeldung bei der Behördeg Einordnung des Produktes gemäß Definition, dann in der Regel
Selbstzertifizierung für CE mark („self-declaration of conformity”) Haupt-Komponenten: Qualitäts-Sicherungs-System, technische
Dokumentation und Nachverfolgungs-System nach Herstellung
29
IVD-Einordnung Jedes Medizinprodukt, das als Reagenz, Reagenzprodukt,
Kalibriermaterial, Kontrollmaterial, Kit, Instrument, Apparat, G ät d S t i l d i V bi d it i dGerät oder System - einzeln oder in Verbindung miteinander -nach der vom Hersteller festgelegten Zweckbestimmung zur In-vitro-Untersuchung von aus dem menschlichen Körpervitro-Untersuchung von aus dem menschlichen Körper stammenden Proben, einschließlich Blut- und Gewebespenden, verwendet wird und ausschließlich oder hauptsächlich dazu pdient, Informationen zu liefern über physiologische oder pathologische Zustände oderp y g p g über angeborene Anomalien oder zur Prüfung auf Unbedenklichkeit und Verträglichkeit bei den g g
potentiellen Empfängern oder zur Überwachung therapeutischer Maßnahmen.g p
30
Vielen Dank!